CURE vs. DGS
CURE (Direxion Daily Healthcare Bull 3x Shares) and DGS (WisdomTree Emerging Markets SmallCap Dividend Fund) are both exchange-traded funds - CURE is a Leveraged Equities fund tracking the Health Care Select Sector Index (300%), while DGS is a Emerging Markets Diversified fund tracking the WisdomTree Emerging Markets SmallCap Dividend Index. Both are passively managed. Over the past 10 years, CURE returned 13.49%/yr vs 10.14%/yr for DGS. At a 0.48 correlation, their price movements are largely independent. CURE charges 1.08%/yr vs 0.58%/yr for DGS.
Performance
CURE vs. DGS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE achieves a -7.96% return, which is significantly lower than DGS's 14.94% return. Over the past 10 years, CURE has outperformed DGS with an annualized return of 13.49%, while DGS has yielded a comparatively lower 10.14% annualized return.
CURE
- 1D
- -0.55%
- 1M
- 13.71%
- YTD
- -7.96%
- 6M
- -6.00%
- 1Y
- 28.51%
- 3Y*
- 3.05%
- 5Y*
- 1.51%
- 10Y*
- 13.49%
DGS
- 1D
- 0.65%
- 1M
- 1.51%
- YTD
- 14.94%
- 6M
- 17.07%
- 1Y
- 25.61%
- 3Y*
- 15.36%
- 5Y*
- 8.06%
- 10Y*
- 10.14%
CURE vs. DGS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CURE Direxion Daily Healthcare Bull 3x Shares | -7.96% | 22.55% | -8.47% | -9.40% | -20.51% | 88.30% | 5.02% | 55.66% | 2.82% | 69.32% |
DGS WisdomTree Emerging Markets SmallCap Dividend Fund | 14.94% | 21.18% | 1.13% | 19.08% | -12.35% | 15.33% | 4.06% | 18.90% | -16.52% | 37.47% |
Correlation
The correlation between CURE and DGS is 0.32, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.32 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.38 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.44 |
Correlation (All Time) Calculated using the full available price history since Jun 15, 2011 | 0.48 |
The correlation between CURE and DGS shifts across timeframes, from 0.32 (3 years) to 0.48 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE vs. DGS — Risk / Return Rank
CURE
DGS
CURE vs. DGS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Direxion Daily Healthcare Bull 3x Shares (CURE) and WisdomTree Emerging Markets SmallCap Dividend Fund (DGS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CURE | DGS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.84 | ||
| Sortino ratioReturn per unit of downside risk | -0.84 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.27 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.85 | 2.38 | -1.52 |
| Martin ratioReturn relative to average drawdown | 1.94 | 7.84 | -5.90 |
Loading charts...
Drawdowns
CURE vs. DGS - Drawdown Comparison
The maximum CURE drawdown since its inception was -69.19%, which is greater than DGS's maximum drawdown of -61.83%. Use the drawdown chart below to compare losses from any high point for CURE and DGS.
Loading charts...
Drawdown Indicators
| CURE | DGS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.19% | -61.83% | -7.36% |
Max Drawdown (1Y)Largest decline over 1 year | -31.10% | -10.06% | -21.04% |
Max Drawdown (3Y)Largest decline over 3 years | -51.93% | -19.31% | -32.62% |
Max Drawdown (5Y)Largest decline over 5 years | -52.23% | -24.86% | -27.37% |
Max Drawdown (10Y)Largest decline over 10 years | -69.19% | -44.08% | -25.11% |
Current DrawdownCurrent decline from peak | -26.94% | -1.05% | -25.89% |
Average DrawdownAverage peak-to-trough decline | -18.16% | -12.57% | -5.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.71% | 3.05% | +10.66% |
Volatility
CURE vs. DGS - Volatility Comparison
Direxion Daily Healthcare Bull 3x Shares (CURE) has a higher volatility of 14.30% compared to WisdomTree Emerging Markets SmallCap Dividend Fund (DGS) at 7.30%. This indicates that CURE's price experiences larger fluctuations and is considered to be riskier than DGS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE | DGS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.30% | 7.30% | +7.00% |
Volatility (6M)Calculated over the trailing 6-month period | 30.87% | 14.27% | +16.60% |
Volatility (1Y)Calculated over the trailing 1-year period | 44.32% | 16.60% | +27.72% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.84% | 15.08% | +28.76% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 49.59% | 17.39% | +32.20% |
CURE vs. DGS - Expense Ratio Comparison
CURE has a 1.08% expense ratio, which is higher than DGS's 0.58% expense ratio.
Dividends
CURE vs. DGS - Dividend Comparison
CURE's dividend yield for the trailing twelve months is around 1.16%, less than DGS's 3.20% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CURE Direxion Daily Healthcare Bull 3x Shares | 1.16% | 1.12% | 1.17% | 2.02% | 0.38% | 0.02% | 0.17% | 0.40% | 0.70% | 0.18% | 0.00% | 0.00% |
DGS WisdomTree Emerging Markets SmallCap Dividend Fund | 3.20% | 3.45% | 3.36% | 4.55% | 5.34% | 3.98% | 3.69% | 3.95% | 4.24% | 2.81% | 3.42% | 3.28% |
Frequently Asked Questions
CURE and DGS have a correlation of 0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CURE has higher volatility (14.30%) compared to DGS (7.30%). In terms of maximum drawdown, CURE dropped -69.19% vs DGS's -61.83%.
On 10-year performance, CURE leads with 13.49% vs 10.14% for DGS. On fees, DGS is cheaper at 0.58% per year. On volatility, DGS has been the lower-risk option at 7.30%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, CURE has performed better with a 13.49% return vs 10.14%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
DGS is cheaper with a 0.58% expense ratio, compared with 1.08% for CURE.
DGS has the higher dividend yield at 3.20%, compared with 1.16% for CURE.
CURE is categorized as Leveraged Equities, while DGS is Emerging Markets Diversified. CURE tracks Health Care Select Sector Index (300%), while DGS tracks WisdomTree Emerging Markets SmallCap Dividend Index. They also come from different issuers: Direxion and WisdomTree. Their fees differ too: 1.08% for CURE and 0.58% for DGS.
DGS currently has the higher Sharpe Ratio (1.44 vs 0.60), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CURE and DGS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer